The Food and Drug Administration has approved Moderna’s first mRNA-based seasonal influenza vaccine, mFLUSIVA (mRNA-1010), for use in adults aged 50 years and older. The regulatory authorisation includes traditional/full approval for people aged 50–64 and an accelerated approval pathway for adults aged 65 and older, which requires additional post‑approval evidence to confirm clinical effectiveness.
Regulatory approval for the 50–64 age group was based on a randomized phase 3 clinical trial that enrolled more than 40,000 adults aged 50 and older across 11 countries. Approximately half of participants received mFLUSIVA and half received a licensed standard‑dose flu vaccine. The trial outcome showed that mFLUSIVA was superior to the standard‑dose vaccine at preventing influenza-like illness confirmed by RT‑PCR testing. Reported relative vaccine efficacy in the trial for adults 50–64 was approximately 27% greater for mFLUSIVA versus the comparator.
For adults aged 65 and older, mFLUSIVA received accelerated approval based on a separate study of over 2,900 U.S. adults that compared immune responses after mFLUSIVA with responses after a high‑dose inactivated influenza vaccine. Those data supported accelerated approval pending confirmatory clinical‑outcome evidence in the older age group.
Influenza causes substantial morbidity and mortality in the United States. According to recent CDC estimates cited in the source, the 2024–2025 season saw about 45,000 flu‑related deaths, and vaccination that season was estimated to have prevented roughly 12,000 deaths. Because the phase 3 evidence indicates improved effectiveness over a standard‑dose vaccine in older adults, mFLUSIVA could contribute to further reductions in influenza‑related severe outcomes among adults 50 and older if real‑world effectiveness is sustained.
Clinical commentators in the article described the approval as a meaningful addition to the influenza prevention toolkit, particularly given the increasing risk of serious complications with advancing age and the potential for mRNA technology to be applied beyond COVID‑19 vaccines.
Traditional egg‑based influenza vaccine manufacturing can take at least six months from strain selection to finished product. The article highlights that mRNA vaccine platforms can be produced more quickly, offering a theoretical advantage in responding to rapidly changing influenza virus strains. Faster redesign and manufacture could reduce the likelihood of vaccine‑virus mismatch in seasons when circulating strains shift during the production window.
Experts framed this as a potentially important technological advantage that may become increasingly valuable for seasonal influenza control and for preparedness against future influenza pandemics if the platform performs well in real‑world use.
Adverse events reported in Moderna’s clinical program included headache, fatigue, joint pain, muscle pain, nausea, vomiting, fever, chills, and injection‑site reactions. The article notes that, as with other vaccines, rare severe allergic reactions such as anaphylaxis can occur.
No new safety concerns were identified in the phase 3 trial in adults aged 50–64, per the reporting in the source material. For adults aged 65 and older, the accelerated approval requires ongoing post‑approval data collection to further characterise clinical outcomes and safety in that age group.
Moderna advises that individuals discuss vaccination with a healthcare professional and disclose specific medical histories that may alter the risk–benefit assessment. Relevant considerations include:
Moderna recommends that people who have had a severe reaction to any ingredient of mFLUSIVA should not receive the vaccine. As always, clinicians should evaluate individual circumstances and provide personalised recommendations on vaccine choice and timing.
The article stresses that mFLUSIVA is not intended to immediately replace existing influenza vaccines. Experts described the product as an additional evidence‑based option that expands choices for protecting adults at higher risk of complications. Because approval for those aged 65 and older was accelerated and requires confirmatory outcome data, some clinicians and commentators expressed the need for one or two seasons of real‑world evidence before declaring superiority over established enhanced vaccines for older adults.
For the upcoming seasons, the priority remains ensuring patients receive an appropriate influenza vaccine rather than waiting for a specific formulation.
Moderna expects mFLUSIVA to be available in the United States for the 2026–2027 respiratory virus season. Clinicians should plan to discuss vaccine options with eligible patients aged 50 and older and prioritise timely vaccination according to established public‑health guidance. Post‑approval surveillance and confirmatory studies—particularly in adults 65 and older—will inform longer‑term positioning of mFLUSIVA among other influenza vaccine choices.
Clinicians can counsel patients that mFLUSIVA represents a new platform with potential advantages in speed of production and preliminary superior efficacy in the trial population aged 50–64, while also reviewing reported side effects, contraindications, and the need for ongoing evidence generation in the oldest age group.